MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Saturday, February 8, 2014

Experimental Drug Proves Effective As Secondary Progressive Multiple Sclerosis Treatment

MIS416 secondary progressive multiple sclerosisNew Zealand-based Innate Immunotherapeutics has been in the news as of late, making headlines about the drug developer’s innovative R&D into testing and developing a viable treatment option for secondary progressive multiple sclerosis. Most recently, new reports of the company’s lead experimental drug for secondary progressive multiple sclerosis, MIS416, has revealed promising results in studies led by researchers at  Victoria University of Wellington.
The study, which was conducted at Victoria and published online in PLOS ONE, revealed that Innate Immunotherapeutics’ MIS416, developed originally to treat the relapsing-remitting form of MS, has been shown to help patients with secondary progressive MS as well. The team of researchers, which includes Dr. Anne La Flamme, Associate Professor in Victoria’s School of Biological Sciences and head of the MS Research Programme at the Malaghan Institute of Medical Research, Dr. Gill Webster from Innate Immunotherapeutics, and PhD student Madeleine White, admit that while their study proved that the drug is indeed efficacious in the treatment of secondary progressive multiple sclerosis, the team still does not fully understand what makes the therapy effective.
“We know this drug works, but we are not sure why,” Dr La Flamme said. ”This study has helped us understand the pathways that are driving the disease and how the medication alters the immune system, giving us a better idea of why MIS416 works as well as insight into how to treat patients and predict who will do better on this sort of medication.”
Dr. La Flamme went on to explain that the majority of cutting-edge research into the treatment of MS is focused on T-cells. However, the new Victoria study reveals that targeting other cells in the central nervous system can significantly reduce advanced forms of MS, such as secondary progressive multiple sclerosis.Secondary Progressive Multiple Sclerosis.
Opexa Therapeutics is currently recruiting nationwide for a clinical trial of its investigational therapy for the treatment of Secondary Progressive Multiple Sclerosis. Get more information about the trial by clicking the icon below:


……..




To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------
Donate Now Please - Click here
Thank you    
…………………….
.

No comments: